BERGENBIO ASA Bergen , Norway, 4 November 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the third quarter 2021 on Tuesday 16 November 2021. The briefing will take place at10:00 am CET at:Carnegie AS , Fjordalleen 16, Aker Brygge, 5th Floor,Oslo where BerGenBio's senior management team will provide an update on the Company followed by a Q&A session. To attend in person please register by mail to hanna.haug@carnegie.no The presentation will webcast live and a link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished. The third quarter report and presentation will be available on the Company's website in the Investors/Financial Reports section from7:00 am CET the same day. -Ends- ContactsMartin Olin Chief Executive Officer,BerGenBio ASA ir@bergenbio.comRune Skeie Chief Financial Officer,BerGenBio ASA rune.skeie@bergenbio.com International Media RelationsMary-Jane Elliott ,Chris Welsh ,Lucy Featherstone Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 About BerGenBio ASABerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in -class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID -19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel,BerGenBio is developing companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition. This is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.BerGenBio is based inBergen, Norway with a subsidiary inOxford, UK . The company is listed on theOslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
